OverviewSuggest Edit

Brainsway engages in the development and provision of technology solutions for non-invasive treatment of brain disorders. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive-compulsive disorders, and stroke rehabilitation.

TypePublic
Founded2003
HQJerusalem, IL
Websitebrainsway.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Jul 2021)100
Revenue (FY, 2020)$22.1 M(-4%)
Share Price (Sept 2021)$8
Cybersecurity ratingBMore

Key People/Management at Brainsway

Hadar Levy

Hadar Levy

Senior VP and GM of North America
Christopher R. von Jako

Christopher R. von Jako

President and Chief Executive Officer (CEO)
Christopher Boyer

Christopher Boyer

VP of Global Marketing
Scott Areglado

Scott Areglado

Senior VP and Chief Financial Officer (CFO)
Amit Ginou

Amit Ginou

VP and Site Manager
Yiftach Roth

Yiftach Roth

Chief Scientific Officer (CSO)
Show more

Brainsway Office Locations

Brainsway has offices in Jerusalem and Cresskill
Jerusalem, IL (HQ)
Hartom St 19
Cresskill, NJ, US
300 Knickerbocker Rd #2300
Show all (2)

Brainsway Financials and Metrics

Brainsway Revenue

Brainsway's revenue was reported to be $22.06 m in FY, 2020
USD

Revenue (FY, 2020)

22.1m

Gross profit (FY, 2020)

17.0m

Gross profit margin (FY, 2020), %

77.1%

Market capitalization (6-Sept-2021)

131.6m

Closing stock price (6-Sept-2021)

8.0

Cash (31-Dec-2020)

17.0m
Brainsway's current market capitalization is $131.6 m.
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

11.1m16.4m23.1m22.1m

Revenue growth, %

47%

Cost of goods sold

2.6m3.6m5.1m5.1m

Gross profit

8.6m12.8m18.0m17.0m
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

14.5m9.0m21.7m17.0m

Accounts Receivable

2.4m2.9m

Current Assets

17.9m13.5m28.8m24.3m

PP&E

7.1m7.6m4.2m4.4m
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(7.1m)(6.5m)(10.3m)(5.4m)

Depreciation and Amortization

1.1m1.2m1.7m1.5m

Accounts Payable

310.0k859.0k

Cash From Operating Activities

(3.5m)(3.8m)(7.2m)(1.4m)
USDFY, 2017

Financial Leverage

2.1 x
Show all financial metrics

Brainsway Operating Metrics

FY, 2018

Patent Applications

29

Patents (Foreign)

25

Patents (US)

16

Projects in Development

7
Show all operating metrics

Brainsway Acquisitions / Subsidiaries

Company NameDateDeal Size
Brain Research and Development Services LTD
Brainsway USA Inc

Brainsway Revenue Breakdown

Embed Graph

Brainsway revenue breakdown by geographic segment: 6.7% from Europe, 88.3% from U.S. and 5.0% from Other

Brainsway Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Brainsway Online and Social Media Presence

Embed Graph

Brainsway News and Updates

BrainsWay to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass. and JERUSALEM, Aug. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President a…

FDA Clears BrainsWay Deep TMS™ System for Decreasing Anxiety Symptoms in Depressed Patients

Expanded Depression Indication Further Demonstrates Company’s Leadership Position Expanded Depression Indication Further Demonstrates Company’s Leadership Position

BrainsWay Hosting Key Opinion Leader Webinar on its Deep TMS™ Therapy for Treating Mental Health Disorders

BURLINGTON, Mass. and JERUSALEM, Aug. 17, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will host a key opinion leader (KOL) …

BrainsWay Reports Second Quarter 2021 Financial Results and Operational Highlights

Strong Revenue Growth of 45% Year-over-Year in Q2 2021

BrainsWay to Report Second Quarter 2021 Financial Results on August 11, 2021

CRESSKILL, N.J. and JERUSALEM, July 28, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2021 fin…

BrainsWay to Present at the Ladenburg Thalmann 2021 Healthcare Conference

CRESSKILL, N.J. and JERUSALEM, July 06, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and…
Show more

Brainsway Blogs

Bilateral repetitive transcranial magnetic stimulation with the H-coil in Parkinson’s Disease: A randomized, sham-controlled Study

Background: Pilot open-label application of high-frequency Deep TMS in Parkinson’s Disease (PD) has shown promising results. Objective: To evaluate safety and efficacy of high-frequency Deep TMS in PD in a double-blind, placebo-controlled, randomized study. Methods: Sixty patients with PD were rando…

A functional magnetic resonance imaging investigation of prefrontal cortex deep transcranial magnetic stimulation efficacy in adults with attention deficit/hyperactive disorder: A double blind, randomized clinical trial

Background: ADHD is one of the most prevalent neurocognitive disorders. Deep TMS is a non-invasive neuromodulation tool that holds promise in treatment of neurocognitive disorders. Hypoactivity of the prefrontal cortex (PFC) has been observed in ADHD. Objective: This study examined the clinical, cog…

Repetitive Transcranial Magnetic Stimulation for Smoking Cessation: a Pivotal Multicenter Double-Blind Randomized Controlled Trial

Background: Deep TMS is a non-invasive brain stimulation method increasingly used to treat psychiatric disorders, primarily depression. Initial studies suggest that Deep TMS may help to treat addictions, but evaluation in multicenter randomized controlled trials (RCTs) is needed. Objective: This mul…

Mental Health and Technological Advancements

The idea of mental health and technology often conjures the image of apathetic teenagers staring into their phones, at the expense of direct, in-person interaction. Yet a more complex view of the interaction between our well-being and the technological advancements of the current era finds that, tog…

Breakthroughs in OCD Treatment

Certain recent developments in the field of mental health are being closely examined as possible breakthroughs in OCD treatment. Read on to find out more about these cutting-edge advancements. OCD: Basic Facts and Figures Obsessive-compulsive disorder (or OCD) is a mental health disorder mainly comp…

How to Improve Your Mental Health

Searching for greater content with one’s life, more and more individuals have turned their attention to the realm of mental health in an attempt to improve their overall well-being. Continue reading if you, like many others, want to learn how to improve your mental health. Mental Health and Overall …
Show more

Brainsway Frequently Asked Questions

  • When was Brainsway founded?

    Brainsway was founded in 2003.

  • Who are Brainsway key executives?

    Brainsway's key executives are Hadar Levy, Christopher R. von Jako and Christopher Boyer.

  • How many employees does Brainsway have?

    Brainsway has 100 employees.

  • What is Brainsway revenue?

    Latest Brainsway annual revenue is $22.1 m.

  • What is Brainsway revenue per employee?

    Latest Brainsway revenue per employee is $220.6 k.

  • Who are Brainsway competitors?

    Competitors of Brainsway include Mediplasma, Gentaur and ACEA Biosciences.

  • Where is Brainsway headquarters?

    Brainsway headquarters is located at Hartom St 19, Jerusalem.

  • Where are Brainsway offices?

    Brainsway has offices in Jerusalem and Cresskill.

  • How many offices does Brainsway have?

    Brainsway has 2 offices.